Introduction {#section5-1753466618787380}
============

Chronic obstructive pulmonary disease (COPD) is a global health problem with a prevalence estimated at 12% among adults.^[@bibr1-1753466618787380],[@bibr2-1753466618787380]^ Besides respiratory symptoms, fatigue is a common symptom in COPD.^[@bibr3-1753466618787380][@bibr4-1753466618787380]--[@bibr5-1753466618787380]^ Fatigue increases by disease severity and also in the presence of comorbidities such as heart disease^[@bibr4-1753466618787380]^ and depressive symptoms.^[@bibr6-1753466618787380]^

We have previously shown that fatigue greatly impacts health-related quality of life (HRQoL) among subjects with and without COPD, when assessed with the generic Short Form-36 (SF-36).^[@bibr7-1753466618787380]^ SF-36 is an extensive questionnaire including 36 questions and is thus less suitable for clinical use. There are also shorter generic^[@bibr8-1753466618787380]^ and also disease-specific HRQoL questionnaires.^[@bibr9-1753466618787380]^ These questionnaires have been used for COPD,^[@bibr8-1753466618787380][@bibr9-1753466618787380]--[@bibr10-1753466618787380]^ but have rarely been evaluated in relation to fatigue.

Besides HRQoL,^[@bibr7-1753466618787380]^ fatigue is also associated with the level of physical activity,^[@bibr11-1753466618787380]^ hospitalization^[@bibr12-1753466618787380]^ and mortality^[@bibr7-1753466618787380]^ among subjects with COPD. Despite the high prevalence and impact of the symptom, fatigue seems to remain unexpressed,^[@bibr13-1753466618787380]^ and is argued to be an important but ignored symptom.^[@bibr14-1753466618787380]^ Fatigue is responsive, for example, to rehabilitation programmes,^[@bibr15-1753466618787380]^ but the lack of simple tools for recognizing fatigue in clinical settings means that possible treatment will not be offered.

There are several instruments to assess fatigue,^[@bibr4-1753466618787380],[@bibr6-1753466618787380]^ but most are too extensive to use in daily clinical practice. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) document recommends the disease-specific COPD Assessment Test (CAT) for assessing the burden of symptoms among patients with COPD.^[@bibr3-1753466618787380]^ According to Jones and colleagues, CAT allows clinicians to identify key areas of health impairments.^[@bibr16-1753466618787380]^ CAT includes eight questions reflecting not only respiratory symptoms and impact on daily life, but also the level of energy. The question regarding level of energy may reflect fatigue, but it has not, as far as we know, been evaluated in relation to validated instruments for assessment of fatigue in a population-based sample.

COPD is an underdiagnosed disease,^[@bibr17-1753466618787380],[@bibr18-1753466618787380]^ but even undiagnosed subjects with COPD have impaired health status,^[@bibr18-1753466618787380]^ and as a consequence, only population-based studies can evaluate the burden of disease. Thus, the primary aim was to evaluate the association between fatigue and HRQoL, assessed with clinically useful instruments, among subjects with and without COPD, and by COPD disease severity, in a population-based study. The secondary aim was to investigate the association between fatigue and the CAT-energy question among subjects with COPD.

Material and methods {#section6-1753466618787380}
====================

Study population {#section7-1753466618787380}
----------------

The recruitment of the Obstructive Lung Disease in Northern Sweden (OLIN) COPD study has previously been described in detail.^[@bibr7-1753466618787380],[@bibr11-1753466618787380],[@bibr19-1753466618787380]^ In short, all subjects with obstructive lung function impairment (FEV~1~/(F)VC \< 0.70) were identified from examinations of population-based cohorts in 2002--2004 (*n* = 993), together with age- and sex-matched referents without obstructive lung function impairment. Since 2005, the study population (*n* = 1986) has been invited to annual clinical examinations with a basic programme including spirometry and a structured interview.

The present study is based on data collected in 2014. In addition to the basic programme, questionnaires for assessment of fatigue as well as generic and disease-specific HRQoL were distributed (*n* = 795). For a few subjects, spirometry (*n* = 21), weight and height (*n* = 12) were not recorded, and in these cases values from the most recent previous examinations were used (year 2010--2013). Subjects not able to participate in the clinical examination were invited for telephone interview (*n* = 165). A study flowchart is presented in [Figure 1](#fig1-1753466618787380){ref-type="fig"}. The study was approved by the Regional Ethical Review Board at Umeå University, Sweden, and the participants provided written informed consent.

![Flowchart for the study population from baseline 2002--2004 to 2014.\
^a^Subjects who refused participation or could not be located at the time of the annual visit.\
^b^Subjects who were not able to attend the clinical examination in 2014.](10.1177_1753466618787380-fig1){#fig1-1753466618787380}

Spirometric classification {#section8-1753466618787380}
--------------------------

Spirometry was performed according to the ATS guidelines,^[@bibr20-1753466618787380]^ using a dry spirometer, the Dutch Mijnhardt Vicatest 5. COPD was defined according to the GOLD-spirometric criteria,^[@bibr3-1753466618787380]^ FEV~1~/FVC \< 0.70, and disease severity by FEV~1~ percentage of predicted; GOLD 1: FEV~1~ ⩾ 80%; GOLD 2: 50% ⩽ FEV~1~ \< 80%; GOLD 3: 30% ⩽ FEV~1~ \< 50%; GOLD 4: FEV~1~ \< 30%. Non-COPD was defined as FEV~1~/FVC ⩾ 0.70. The highest of pre- or post- bronchodilator values were used, and the OLIN reference values for FEV~1~.^[@bibr21-1753466618787380]^

Questionnaires {#section9-1753466618787380}
--------------

The structured interview questionnaire includes well-validated questions regarding respiratory symptoms,^[@bibr4-1753466618787380],[@bibr11-1753466618787380],[@bibr19-1753466618787380]^ and in addition questions regarding smoking habits and comorbidities. The interview questionnaire also includes the modified Medical Research Council (mMRC)-dyspnoea scale, range 0 to 4, where a higher score indicates more dyspnoea.^[@bibr22-1753466618787380]^ Clinically significant dyspnoea was defined as mMRC score ⩾2.^[@bibr3-1753466618787380]^

FACIT-Fatigue is a 13-item scale estimating degree of fatigue previously used,^[@bibr7-1753466618787380],[@bibr23-1753466618787380],[@bibr24-1753466618787380]^ and validated for COPD.^[@bibr25-1753466618787380]^ The total score ranges from 0 to 52, with higher scores representing less fatigue.^[@bibr26-1753466618787380]^ Clinically relevant fatigue has been defined as a score ⩽43.^[@bibr4-1753466618787380]^

EQ-5D is a validated generic instrument for assessment of HRQoL, applicable to the general population as well as a wide range of health conditions including COPD.^[@bibr8-1753466618787380],[@bibr10-1753466618787380]^ The instrument includes two parts: five questions and a vertical visual analogue scale (VAS) ranging from 0, the worst imaginable health, to 100, the best imaginable health. The VAS scale was used in the current study.

The CAT is a validated disease-specific questionnaire designed to provide a simple measure of health status among patients with COPD.^[@bibr9-1753466618787380],[@bibr16-1753466618787380]^ It consists of eight questions covering cough, phlegm, chest tightness, breathlessness, activity limitations at home, confidence leaving home, sleep and energy. The items are graded from 0 to 5, giving a total score range from 0 to 40, where lower scores indicate fewer symptoms and a better HRQoL.^[@bibr27-1753466618787380]^ A score ⩾10 is defined as a cut-off for burden of symptoms where treatment should be considered.^[@bibr3-1753466618787380]^ In the current study the energy question was also analysed separately and henceforth labelled CAT-energy.

Definitions {#section10-1753466618787380}
-----------

Smoking habits were classified as: non-smokers, ex-smokers (stopped at least 12 months ago) and current smokers. Any respiratory symptoms included at least one of the following: chronic cough, chronic productive cough, recurrent wheeze or mMRC dyspnoea ⩾2. Anxiety/depression was defined by affirmative answer to the question 'Do you have anxiety or depression?'. Heart disease was defined as a self-reported history of a least one of the following: angina pectoris, coronary artery bypass, receiving a percutaneous coronary intervention, myocardial infarction or cardiac insufficiency.

Statistical analyses {#section11-1753466618787380}
--------------------

SPSS version 24.0 was used for the statistical analyses (IBM, Armonk, NY). Due to a small number of participants, GOLD 3 and 4 were grouped together. Bivariate comparisons between COPD and non-COPD were made with Chi-square test or independent samples *t* test. Comparisons between COPD and non-COPD across more than two groups were made with the Mantel--Haenszel test-for-trend or analysis of variance (ANOVA). Because of non-normal distribution of FACIT-Fatigue, EQ-5D-VAS and CAT, median scores are presented and the Kruskal--Wallis test was used for comparison of the groups. When significant values were found by the Kruskal--Wallis test, post hoc analyses were made using the Mann--Whitney *U* test with Bonferroni correction. Spearman's rho was used to examine the degree of correlation between the questionnaires. A *p* value of \<0.05 was considered statistically significant.

Factors associated with clinically relevant fatigue were analysed stratified for non-COPD and COPD, by logistic regression, and the associations were expressed as odds ratios (OR) with 95% confidence intervals (CI). The dependent variable in all models was clinically relevant fatigue defined as a FACIT-Fatigue score ⩽43. Covariates included were age, sex, FEV~1~ percentage of predicted, smoking habits, any respiratory symptoms, anxiety/depression, heart disease and health care contacts due to respiratory symptoms. Furthermore, EQ-5D-VAS score (continuous variable), CAT score (continuous variable), CAT score ⩾10, and the CAT-energy question (categories 0--5, with 0 as reference) were included in separate models.

Results {#section12-1753466618787380}
=======

Characteristics of the study population {#section13-1753466618787380}
---------------------------------------

Subjects with COPD were older, had a lower mean body mass index (BMI), included a higher proportion of current smokers and reported any respiratory symptoms more frequently than subjects without COPD. The proportion of subjects that reported healthcare contacts due to respiratory symptoms were higher in COPD. The prevalence of heart disease and anxiety/depression, respectively, were similar in COPD and non-COPD ([Table 1](#table1-1753466618787380){ref-type="table"}).

###### 

Basic characteristics of the study population (*n* = 795) comparing non-COPD and COPD, and by GOLD stage.

![](10.1177_1753466618787380-table1)

  Characteristic                                                                        Non-COPD *n* = 428   COPD *n* = 367   *p* value     GOLD 1 *n* = 177   GOLD 2 *n* = 172   GOLD 3--4 *n* = 18   *p* value^[a](#table-fn1-1753466618787380){ref-type="table-fn"}^
  ------------------------------------------------------------------------------------- -------------------- ---------------- ------------- ------------------ ------------------ -------------------- ---------------------------------------------------------------------
  Female sex, *n* (%)                                                                   195 (55.7)           155 (44.3)       0.346         83 (46.9)          67 (39.0)          5 (27.8)             0.051
  Age (years), mean (SD)                                                                70.0 (9.4)           71.9 (8.9)       **0.004**     72.1 (9.3)         71.6 (8.5)         74.1 (7.8)           0.502^[b](#table-fn1-1753466618787380){ref-type="table-fn"}^
  Age (years), range                                                                    43--94               43--94                         44--94             43--94             60--89               
  FEV~1~ (percentage of predicted), mean (SD)                                           97.0 (13.8)          78.7 (16.9)      **\<0.001**   92.3 (9.6)         68.7 (8.4)         41.0 (7.0)           **\<0.001** ^[b](#table-fn1-1753466618787380){ref-type="table-fn"}^
  BMI (kg/m^2^), mean (SD)                                                              27.6 (4.3)           26.8 (4.3)       **0.005**     26.3 (3.6)         27.3 (4.7)         25.7 (4.9)           **0.036** ^[b](#table-fn1-1753466618787380){ref-type="table-fn"}^
  Current smokers, *n* (%)                                                              27 (6.3)             68 (18.5)        **\<0.001**   22 (12.4)          39 (22.7)          7 (38.9)             **0.001**
  mMRC Dyspnea scale ⩾2, *n* (%)                                                        6 (1.5)              44 (13.1)        **\<0.001**   13 (16.2)          25 (16.2)          6 (37.5)             **0.001**
  Chronic cough, *n* (%)                                                                136 (31.9)           183 (50.3)       **\<0.001**   66 (37.9)          103 (59.9)         14 (77.8)            **\<0.001**
  Chronic productive cough, *n* (%)                                                     134 (31.5)           188 (51.4)       **\<0.001**   77 (43.5)          96 (56.1)          15 (83.3)            **\<0.001**
  Recurrent wheeze, *n* (%)                                                             30 (7.0)             71 (19.3)        **\<0.001**   16 (9.0)           49 (28.5)          6 (33.3)             **\<0.001**
  Any respiratory symptom, *n* (%)                                                      174 (41.6)           238 (65.7)       **\<0.001**   90 (51.7)          132 (77.6)         16 (88.9)            **\<0.001**
  Anxiety/depression, *n* (%)                                                           50 (11.7)            54 (14.8)        0.205         22 (12.4)          31 (18.1)          1 (5.6)              0.155
  Heart disease, *n* (%)                                                                61 (14.3)            67 (18.4)        0.124         25 (14.3)          39 (22.7)          3 (16.7)             0.116
  Clinically relevant fatigue, *n* (%)                                                  120 (28.0)           137 (37.3)       **0.005**     50 (28.2)          75 (43.6)          12 (66.7)            **\<0.001**
  Healthcare contacts, *n* (%)^[c](#table-fn1-1753466618787380){ref-type="table-fn"}^   35 (8.2)             64 (17.4)        **\<0.001**   18 (10.2)          39 (22.7)          7 (38.9)             **\<0.001**

Test for trend . ^b^One-way ANOVA. ^c^Due to respiratory symptoms (last 12 months). Significant values in bold.

ANOVA, analysis of variance; BMI, body mass index; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; mMRC, modified Medical Research Council.

The median FACIT-Fatigue score was lower among subjects with than without COPD (47.0 *versus* 48.0, *p* = 0.006), and GOLD 2 and GOLD 3--4 had lower scores than non-COPD (45.0 *versus* 48.0, *p* = 0.006 and 38.0 *versus* 48.0, *p* = 0.012). The proportion of clinically relevant fatigue was significantly higher among subjects with than without COPD, and increased by GOLD stage ([Table 1](#table1-1753466618787380){ref-type="table"}). The median score for EQ-5D-VAS was similar in non-COPD and COPD, while there was a significant difference when comparing the distributions within the two groups (median 80.0, IQR 71.0--90.0 *versus* median 80.0, IQR 68.0--90.0, *p* = 0.002). Median EQ-5D-VAS differed significantly between GOLD stages; GOLD 1: 81.0, GOLD 2: 75.0, and GOLD 3--4: 72.5 (*p* = 0.004).

FACIT-Fatigue and EQ-5D-VAS among subjects with and without COPD {#section14-1753466618787380}
----------------------------------------------------------------

Moderate to fairly strong correlations were found between the instruments FACIT-Fatigue and EQ-5D-VAS both among subjects with (Spearman's rho = 0.63, *p* \< 0.001) and without COPD (Spearman's rho = 0.65, *p* \< 0.001), and within categories of disease severity; Spearman's rho GOLD 1: 0.51 (*p* \< 0.001), GOLD 2: 0.69 (*p* \< 0.001), GOLD 3--4: 0.54 (*p* = 0.032). The median EQ-5D-VAS scores were significantly lower among subjects with than without clinically relevant fatigue, both in non-COPD and in each of the GOLD stages ([Figure 2](#fig2-1753466618787380){ref-type="fig"}).

![Box plots illustrating median EQ-5D-VAS score (interquartile range) comparing study participants with (FACIT-Fatigue score ⩽43) and without clinically significant fatigue among non-COPD and by COPD disease severity.](10.1177_1753466618787380-fig2){#fig2-1753466618787380}

CAT and FACIT-Fatigue among subjects with COPD {#section15-1753466618787380}
----------------------------------------------

The median CAT score among subjects with COPD was 9.0. Significant differences were found between the GOLD stages (GOLD 1: 6.0, GOLD 2: 10.0, GOLD 3--4: 17.0, *p* \< 0.001). The proportion of subjects with a CAT score ⩾10 was 42.1%, and increased by disease severity: GOLD 1: 28.7%, GOLD 2: 55.2% and GOLD 3--4: 82.4% (*p* \< 0.001).

Correlations between FACIT-Fatigue and CAT were significant among all subjects with COPD (Spearman's rho = −0.60, *p* \< 0.001), and in each of the GOLD stages; Spearman's rho GOLD 1: --0.47 (*p* \< 0.001), GOLD 2: --0.66 (*p* \< 0.001), GOLD 3--4: --0.60 (*p* = 0.011). The median CAT scores and the proportion of subjects with CAT score ⩾10 were higher among subjects with clinically relevant fatigue than among those without (14.0 *versus* 6.0, *p* \< 0.001, and 63.5% *versus* 36.5%, *p* \< 0.001). The findings were similar in each of the GOLD stages (data not shown).

Factors associated with clinically relevant fatigue among subjects with and without COPD {#section16-1753466618787380}
----------------------------------------------------------------------------------------

Unadjusted and adjusted analyses of factors associated with clinically relevant fatigue are shown in [Tables 2](#table2-1753466618787380){ref-type="table"} and [3](#table3-1753466618787380){ref-type="table"}. Clinically relevant fatigue was associated with any respiratory symptoms, anxiety/depression and decreasing EQ-5D-VAS score, among both subjects with and without COPD, also when adjusted for confounders ([Table 2](#table2-1753466618787380){ref-type="table"}). In similar analyses performed among subjects with COPD only, clinically relevant fatigue remained associated with increasing CAT score, and CAT score ⩾10 independent of age, FEV~1~ percentage of predicted, anxiety/depression and heart disease ([Table 3](#table3-1753466618787380){ref-type="table"}, Models 1 and 2).

###### 

Factors associated with clinically relevant fatigue among subjects with and without COPD, expressed as odds ratios (OR) with 95% confidence intervals (CI); unadjusted and adjusted analyses by logistic regression.

![](10.1177_1753466618787380-table2)

                                                                                          Unadjusted analyses      Adjusted analyses                                  
  --------------------------------------------------------------------------------------- ------------------------ -------------------------- ----------------------- -----------------------
  Age^[a](#table-fn3-1753466618787380){ref-type="table-fn"}^                              **1.03 (1.01--1.06)**    **1.04 (1.02--1.07)**      1.02 (0.99--1.05)       1.02 (0.98--1.05)
  Female sex                                                                              1.02 (0.67--1.55)        0.92 (0.60--1.41)                                  
  FEV~1~ percentage of predicted^[a](#table-fn3-1753466618787380){ref-type="table-fn"}^   **0.98 (0.96--0.99)**    **0.97 (0.96--0.98)**      1.00 (0.98--1.02)       0.98 (0.96--1.00)
  Ex-smoker                                                                               1.07 (0.69--1.65)        1.20 (0.74--1.95)                                  
  Current smoker                                                                          0.58 (0.21--1.61)        1.18 (0.63--2.19)                                  
  Any respiratory symptoms                                                                **2.98 (1.91--4.64)**    **3.40 (2.05--5.65)**      **1.80 (1.04--3.13)**   **2.16 (1.02--4.28)**
  Anxiety/depression                                                                      **5.84 (3.13--10.91)**   **2.40 (1.33--4.30)**      **3.06 (1.43--6.55)**   **2.39 (1.11--5.13)**
  Heart disease                                                                           **1.81 (1.03--3.20)**    **2.84 (1.65--4.89)**      0.66 (0.30--1.44)       1.59 (0.76--3.33)
  Healthcare contacts^[b](#table-fn3-1753466618787380){ref-type="table-fn"}^              **2.03 (1.01--4.11)**    1.63 (0.95--2.81)                                  
  EQ-5D-VAS^[a](#table-fn3-1753466618787380){ref-type="table-fn"}^                        **0.92 (0.90--0.94)**    **0.91 (0.89--0.93)**      **0.93 (0.91--0.95)**   **0.92 (0.90--0.94)**
  CAT^[a](#table-fn3-1753466618787380){ref-type="table-fn"}^                                                       **1.24 (1.78--1.30)**                              
  CAT ⩾10                                                                                                          **8.71 (5.34--14.21)**                             
  CAT-energy 1^[c](#table-fn3-1753466618787380){ref-type="table-fn"}^                                              1.74 (0.72--4.19)                                  
  CAT-energy 2^[c](#table-fn3-1753466618787380){ref-type="table-fn"}^                                              **6.05 (2.64--13.83)**                             
  CAT-energy 3^[c](#table-fn3-1753466618787380){ref-type="table-fn"}^                                              **18.44 (7.03--48.35)**                            
  CAT-energy 4^[c](#table-fn3-1753466618787380){ref-type="table-fn"}^                                              **23.60 (6.79--82.01)**                            
  CAT-energy 5^[c](#table-fn3-1753466618787380){ref-type="table-fn"}^                                              **36.88 (3.81--357.10)**                           

Entered as a continuous variable. ^b^Due to respiratory symptoms (last 12 months). ^c^CAT-energy 0 as reference. Significant associations in bold.

CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease.

###### 

Factors associated with clinically relevant fatigue among subjects with COPD, expressed as odds ratios (OR) with 95% confidence intervals (CI); adjusted analyses in logistic regressions models (Models 1--3 evaluating CAT total score, CAT score ⩾10, the CAT-energy score, respectively).

![](10.1177_1753466618787380-table3)

                                                                                          [Adjusted analyses]{.ul}                            
  --------------------------------------------------------------------------------------- -------------------------- ------------------------ --------------------------
  Age^[a](#table-fn5-1753466618787380){ref-type="table-fn"}^                              **1.04 (1.01--1.07)**      **1.04 (1.01--1.07)**    **1.05 (1.02--1.08)**
  FEV~1~ percentage of predicted^[a](#table-fn5-1753466618787380){ref-type="table-fn"}^   0.99 (0.98--1.01)          0.99 (0.97--1.00)        0.99 (0.97--1.00)
  Any respiratory symptoms^[b](#table-fn5-1753466618787380){ref-type="table-fn"}^         0.81 (0.43--1.53)          1.46 (0.77--2.75)        **1.87 (1.01--3.44)**
  Anxiety/depression                                                                      **2.26 (1.09--4.68)**      **2.33 (1.16--4.70)**    **2.38 (1.18--4.81)**
  Heart disease                                                                           **2.26 (1.16--4.44)**      **2.58 (1.34--4.96)**    **2.53 (1.31--4.89)**
  CAT^[a](#table-fn5-1753466618787380){ref-type="table-fn"}^                              **1.21 (1.15--1.29)**                               
  CAT ⩾10                                                                                                            **6.54 (3.72--11.50)**   
  CAT-energy 1^[c](#table-fn5-1753466618787380){ref-type="table-fn"}^                                                                         1.71 (0.65--4.48)
  CAT-energy 2^[c](#table-fn5-1753466618787380){ref-type="table-fn"}^                                                                         **4.79 (1.90--12.12)**
  CAT-energy 3^[c](#table-fn5-1753466618787380){ref-type="table-fn"}^                                                                         **15.32 (5.24--44.80)**
  CAT-energy 4^[c](#table-fn5-1753466618787380){ref-type="table-fn"}^                                                                         **17.77 (4.54--69.56)**
  CAT-energy 5^[c](#table-fn5-1753466618787380){ref-type="table-fn"}^                                                                         **29.66 (2.56--344.15)**

Entered as a continuous variable. ^b^When any respiratory symptoms was admitted from Models 1 and 2, the other estimates remained at the same level. ^c^CAT-energy 0 as reference. Significant associations in bold.

CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease.

Clinically relevant fatigue and CAT-energy among subjects with COPD {#section17-1753466618787380}
-------------------------------------------------------------------

The proportion of subjects with clinically relevant fatigue increased by increasing CAT-energy score: 0: 11.9%; 1: 19.1%; 2: 45.0%; 3: 71.4%; 4: 76.2%; and 5: 83.3% (*p* \< 0.001). [Figure 3](#fig3-1753466618787380){ref-type="fig"} illustrates median (IQR) FACIT-Fatigue score by CAT-energy score, with a line depicting clinically relevant fatigue; CAT-energy scores of ⩾3 were below the cut-off for clinically relevant fatigue. When analysed in a logistic regression model, CAT-energy scores ⩾2 were significantly associated with clinically relevant fatigue independent of age, FEV~1~ percentage of predicted, any respiratory symptoms, anxiety/depression and heart disease ([Table 3](#table3-1753466618787380){ref-type="table"}, Model 3).

![Box plots illustrating median FACIT-Fatigue score (IQR) among subjects with COPD by CAT-energy question score (0--5, higher score indicating less energy). The line depicts clinically relevant fatigue (FACIT-Fatigue score ⩽43).\
Kruskal--Wallis test comparing FACIT-Fatigue score between the CAT-energy scores 0--5, *p* \< 0.001.](10.1177_1753466618787380-fig3){#fig3-1753466618787380}

Discussion {#section18-1753466618787380}
==========

In this population-based study, clinically relevant fatigue was related to worse HRQoL among both subjects with and without COPD, and in all GOLD stages. Clinically relevant fatigue was also independently associated with respiratory symptoms and anxiety/depression. Among subjects with COPD, clinically relevant fatigue was associated with increasing CAT score as well as CAT score ⩾10 independent of age, FEV~1~ percentage of predicted, anxiety/depression and heart disease. CAT-energy question scores ⩾2 were associated with clinically relevant fatigue independent of confounders. Thus, CAT-energy score seems to be a marker of clinically relevant fatigue, and may be a screening tool for fatigue among patients with COPD in clinical practice.

In line with more complex generic HRQoL questionnaires,^[@bibr7-1753466618787380]^ also the simple EQ-5D-VAS could demonstrate that subjects with clinically relevant fatigue had a worse HRQoL than those without, both among subjects with and without COPD. Similar results were found in a hospital sample of COPD patients when using the disease-specific and comprehensive St. George's Respiratory Questionnaire; HRQoL was worse among fatigued patients.^[@bibr6-1753466618787380]^ The EQ-5D-VAS may be an easy-to-use tool compared to more time-consuming instruments when evaluating HRQoL among patients with COPD in clinical practice.^[@bibr10-1753466618787380]^ According to our results, it also seems to be sensitive enough to detect impaired health status due to fatigue in a population derived from a population-based setting including mainly mild to moderate COPD.

The disease-specific CAT questionnaire is, in accordance with the GOLD document, recommended to assess the burden of symptoms and HRQoL among patients with COPD in clinical practice.^[@bibr3-1753466618787380]^ The CAT scores can indicate acute deterioration in HRQoL, exacerbations, depressions and mortality among patients with COPD according to a recently published review.^[@bibr9-1753466618787380]^ Furthermore, the CAT scores had a fairly strong correlation with FACIT-Fatigue scores in a primary care population of COPD,^[@bibr27-1753466618787380]^ and explained almost 50% of the variation in FACIT-Fatigue in the current study. To the best of our knowledge, our study is the first to demonstrate that there is an association between clinically relevant fatigue and CAT scores among subjects with COPD in a population-based sample. Both increasing CAT score and a CAT score ⩾10 were associated with clinically relevant fatigue, independent of anxiety/depression, heart disease and other confounders. These results suggest that a higher CAT score -- that is a higher burden of symptoms and worse HRQoL -- is associated with fatigue.

In our study, FEV~1~ percentage of predicted was not an independent risk factor for clinically relevant fatigue, while respiratory symptoms and comorbidities seems to be of importance among subjects with and without COPD. The relationship between airflow limitation and HRQoL seems to be weak,^[@bibr3-1753466618787380],[@bibr28-1753466618787380]^ and similar findings have been found among stable patients with COPD -- that is, there were no correlations between fatigue and disease severity assessed as FEV~1~ percentage of predicted or GOLD staging.^[@bibr24-1753466618787380]^ In the latter study, the lack of correlation between fatigue and severity of disease was suggested to be related to an adaptation to chronic impairment. In our COPD population, clinically relevant fatigue was independently associated with anxiety/depression and heart disease. These are common comorbidities in COPD, known to be associated with fatigue,^[@bibr3-1753466618787380],[@bibr4-1753466618787380],[@bibr6-1753466618787380],[@bibr7-1753466618787380],[@bibr24-1753466618787380]^ which highlights the importance of identifying and treating comorbidities that are related to fatigue to relieve the symptom.^[@bibr6-1753466618787380]^ In the current study anxiety/depression was defined using the simple question 'Do you have anxiety or depression?', while most others have used more complex anxiety and depression questionnaires.^[@bibr6-1753466618787380],[@bibr24-1753466618787380]^ Thus a positive answer to a simple question regarding anxiety/depression may serve as a gateway for further evaluation of depressive symptoms and fatigue.

Even though fatigue is common in COPD and has an impact on health status, it is often unexpressed^[@bibr13-1753466618787380]^ and not recognized,^[@bibr14-1753466618787380]^ which is why active screening for fatigue is important.^[@bibr5-1753466618787380],[@bibr7-1753466618787380]^ It is known that fatigue can be improved by physical activity, relaxation exercises and other non-pharmacological interventions.^[@bibr15-1753466618787380],[@bibr29-1753466618787380],[@bibr30-1753466618787380]^ By recognizing fatigue in patients with COPD, individual treatment regimens can be initiated and can contribute to improved HRQoL. In the current study the CAT-energy question was associated with fatigue; the proportion of subjects with clinically relevant fatigue increased by increasing CAT-energy score. Almost every other subjects with a score of 2 in the CAT-energy question had clinically relevant fatigue, and more than two out of three with CAT-energy score 3 or higher. Thus the CAT-energy question may be a simple screening tool for fatigue among patients with COPD, and we suggest a cut-off point of 2--3 to be further evaluated.

Strengths and limitations {#section19-1753466618787380}
-------------------------

The strengths of this study are the use of both generic and disease-specific well-validated short and simple instruments useful in clinical practice.^[@bibr10-1753466618787380],[@bibr16-1753466618787380]^ Furthermore, the spirometric criteria for COPD were based on post-bronchodilator spirometry as recommended by guidelines.^[@bibr3-1753466618787380]^ Another strength is the population-based study design; our COPD population is dominated by mild to moderate disease, corresponding to the distribution of severity in the general population.^[@bibr3-1753466618787380]^ The results are not affected by the well-known underdiagnosis^[@bibr17-1753466618787380],[@bibr18-1753466618787380]^ and are thus expected to be generalizable to COPD in society.

There are also limitations. Data were obtained from a longitudinal study in which 526 subjects died before 2014 and a healthy survivor effect must be taken into account. In a previous publication based on the same cohort it was reported that the deceased subjects were older, and had a higher prevalence of productive cough and heart disease, which strengthens the assumption of a healthy survivor effect.^[@bibr31-1753466618787380]^ However, the consequence is that the results may be underestimated, and despite an expected healthy survivor effect there were relationships strong enough to show statistical significance.

Another limitation is that we used reported health care contacts due to respiratory symptoms as a proxy for exacerbations, and there was no obvious association with fatigue. This finding contrasts with others, as increased fatigue has been related to exacerbation frequency,^[@bibr24-1753466618787380]^ and is a strong risk factor for hospitalization and length of hospital admission.^[@bibr12-1753466618787380]^ In other words, fatigue has been shown to be associated to outcomes that are important for the economic burden in COPD.^[@bibr32-1753466618787380]^ However, there is a lack of studies about fatigue in relation to healthcare costs, a context that requires further studies.

Conclusion {#section20-1753466618787380}
==========

In this population-based study, clinically relevant fatigue was associated with worse HRQoL among subjects with and without COPD when using the clinically useful generic instrument EQ-5D-VAS. Respiratory symptoms and anxiety/depression seem to have important impacts, since these factors were independently associated with clinically relevant fatigue. Among subjects with COPD, clinically relevant fatigue was independently associated with increasing CAT score, CAT score ⩾10, increasing age, anxiety/depression and heart disease. However, disease severity, expressed as FEV~1~ percentage of predicted, did not remain associated with clinically relevant fatigue when adjusted for confounders. The CAT-question evaluating patients' energy levels was associated with clinically relevant fatigue; about every other with a score of 2, and more than two out of three with a score ⩾3 were affected. We suggest that the CAT-energy question may be a possible screening tool for fatigue among patients with COPD, using a cut-off of 2--3 points.
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